Randall Stevens

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and…

Journal of the American Academy of Dermatology · 2015 · 504 citations

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

Annals of the Rheumatic Diseases · 2014 · 345 citations